海森药业
(001367)
| 流通市值：32.22亿 | | | 总市值：40.36亿 |
| 流通股本：1.22亿 | | | 总股本：1.52亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 532,259,379.46 | 358,867,170.35 | 242,085,860.34 | 118,478,458.16 |
| 营业收入 | 532,259,379.46 | 358,867,170.35 | 242,085,860.34 | 118,478,458.16 |
| 二、营业总成本 | 381,201,958.18 | 259,594,428.66 | 172,703,186.5 | 83,568,452.19 |
| 营业成本 | 289,549,165.67 | 195,283,235.55 | 134,299,857.47 | 66,096,444.72 |
| 税金及附加 | 4,579,765.7 | 3,602,364.85 | 2,316,429.81 | 1,014,074.35 |
| 销售费用 | 16,199,675.79 | 11,177,580.16 | 6,736,212.56 | 2,561,780.56 |
| 管理费用 | 37,032,877.28 | 25,676,117.04 | 15,493,232.38 | 7,009,664.4 |
| 研发费用 | 38,860,884.85 | 28,166,061.59 | 17,710,879.4 | 9,441,180.96 |
| 财务费用 | -5,020,411.11 | -4,310,930.53 | -3,853,425.12 | -2,554,692.8 |
| 其中:利息费用 | 346,049.03 | 259,161.14 | 172,786.65 | 84,933 |
| 其中:利息收入 | 5,682,222.2 | 3,998,299.29 | 3,078,235.75 | 1,918,551.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,695,000 | - | - | - |
| 加:投资收益 | 5,017,801.56 | 2,661,019.51 | 568,726.36 | 213,663.34 |
| 资产减值损失(新) | -698,845.1 | -400,198.32 | -256,904.14 | -13,758.75 |
| 信用减值损失(新) | -2,752,614.01 | -566,718.5 | -448,213.25 | 45,086.1 |
| 其他收益 | 2,526,733.97 | 1,225,917.9 | 979,474.51 | 657,757.39 |
| 四、营业利润 | 156,845,497.7 | 102,192,762.28 | 70,225,757.32 | 35,812,754.05 |
| 加:营业外收入 | 584,787.81 | 571,268.1 | 566,788.1 | 501,168.49 |
| 减:营业外支出 | 673,268.02 | 397,454.54 | 298,548.8 | 125,015.55 |
| 五、利润总额 | 156,757,017.49 | 102,366,575.84 | 70,493,996.62 | 36,188,906.99 |
| 减:所得税费用 | 20,877,351.71 | 14,156,958.55 | 9,699,843.31 | 4,976,725.4 |
| 六、净利润 | 135,879,665.78 | 88,209,617.29 | 60,794,153.31 | 31,212,181.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 135,879,665.78 | 88,209,617.29 | 60,794,153.31 | 31,212,181.59 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 135,879,665.78 | 88,209,617.29 | 60,794,153.31 | 31,212,181.59 |
| 扣除非经常损益后的净利润 | 128,101,268.76 | 84,757,978.97 | 59,250,179.17 | 30,151,743.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.91 | 0.59 | 0.41 | 0.31 |
| (二)稀释每股收益 | 0.89 | 0.58 | 0.4 | 0.3 |
| 九、综合收益总额 | 135,879,665.78 | 88,209,617.29 | 60,794,153.31 | 31,212,181.59 |
| 归属于母公司股东的综合收益总额 | 135,879,665.78 | 88,209,617.29 | 60,794,153.31 | 31,212,181.59 |
| 公告日期 | 2026-03-26 | 2025-10-22 | 2025-08-15 | 2025-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |